Loading organizations...
3W Partners Capital is a Hong Kong-based private equity firm focused on cross-border consolidation and growth within the Chinese economy. It strategically invests across healthcare, consumer, financial services, and technology sectors. The firm engages in privately-negotiated equity and equity investments, targeting long-term capital appreciation by supporting high-potential companies.
Established in Hong Kong in 2013, 3W Partners Capital arose from recognizing strategic opportunities in China's evolving development. Directors Lu Hong Goh and Hoi Hin William Chan have been key to the firm’s leadership. This focus on facilitating cross-border capital deployment and industry consolidation aims to generate value for sophisticated investors.
The firm serves institutional investors and family offices as general partner in various funds. 3W Partners Capital envisions itself as a catalyst for enterprise expansion and innovation in its target sectors. Its long-term objective is to realize significant returns for limited partners by empowering portfolio companies towards sustained industry transformation.
3W Partners has 5 tracked investments across 5 companies. The latest tracked deal is $180.0M Series C in LifeMine Therapeutics in March 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2022 | LifeMine Therapeutics | $180.0M Series C | Fidelity Management & Research Company | ARCH Venture Partners, Foresite Capital, F Prime Capital, GV, Mubadala, Blue Pool Capital, GlaxoSmithKline, Invus, MRL Ventures Fund |
| Oct 20, 2021 | Steadiwear | $890K Seed | 3W Partners | Centre For Aging + Brain Health Innovation, Ontario Brain Institute |
| May 9, 2018 | CStone Pharmaceuticals | $259.2M Series B | GIC | 6 Dimensions Capital, ARCH Venture Partners, AVICT Global, Boyu Capital, CPE, Hillhouse Capital, Hongshan Capital Group (Sequoia Capital China), King Star Capital, Taikang, Terra Magnum Capital Partners, WuXi Healthcare Ventures, Yunfeng Capital |
| Sep 7, 2017 | NextCODE Health | $240.0M Series B | Sequoia Capital | Amgen Ventures, Temasek, Jack MA |
| Jun 14, 2017 | Twist Bioscience | $27.0M Other Equity | — | BAY City Capital, Biomatics Capital, Ditch Plains Capital Management, FIS, GF Xinde Life Science Investment Fund, Kangmei Group, NFT Investment Limited, Reinet Investments |